Erectile dysfunction (ED) is a highly prevalent and increasingly common, mainly vascular disorder. Most patients with chronic cardiovascular diseases experience decreased libido and frequency of sexual activity, as well as ED. Some unique organic and psychological factors contributing to ED have been identified in patients with underlying cardiovascular problems. Certain risk factors are common to the development of coronary artery disease, heart failure and ED, including diabetes mellitus, hypertension, smoking and dyslipidemia. Additionally, the use of medications such as beta blockers, digoxin and thiazide diuretics might eventually cause but more likely worsen sexual dysfunction. These unintended consequences can lead to medical noncompliance in misguided efforts to retain satisfactory sexual activity, and thereby worsen cardiovascular problems. Accordingly, it is important for physicians dealing with patients with cardiovascular diseases to address sexual concerns in their patients. After careful evaluation, most patients with stable cardiac disorders can resume sexual activity and/or can be treated for ED.
Introduction
Erectile dysfunction (ED) represents an increasingly important problem, in particular for the primary care physician, internist and cardiologist for several reasons: (1) patients live longer with chronic diseases such as heart failure, coronary artery disease, diabetes and chronic renal failure among others. (2) More patients with cardiovascular disorders develop ED, or-at least-the reported incidence is higher since general awareness and acceptance as well as potential treatment options are available. (3) Male ED in most cases is considered to be a vascular problem, that is, it represents endothelial dysfunction, which itself might act as an early marker for the existence of coronary artery vascular dysfunction or even coronary artery disease and generalized atherosclerosis. In some groups of men as young as 18 to as old as 59 y, sexual dysfunction was present to some degree in up to 31% of men. 1 Similar numbers have been echoed in other studies, where at 40 y, 40% of men confessed to some degree of sexual dysfunction. 2 Another study also demonstrated that in men, 53-90 y, prevalence of sexual dysfunction in the three preceding months was as high as 33%. 3 This same cohort of men also demonstrated a dramatic decrease in sexual desire, function and orgasm after age 50 y.
Optimal male sexual function requires a host of psychological, hormonal, vascular and neurological agents acting in concert. While normal male sexual function is a complex, simultaneous and continuous interplay of these factors, it is chiefly a vascular phenomenon that begins with an influx of arterial blood into the penile chambers. The corpora cavernosae and the corpus spongiosum are expansive. As they enlarge they eventually compress the venous outflow channels, disallowing blood to escape and resulting in an enlarged and firmer penis. Various substances such as nitric oxide, acting under the influence of enzymes such as nitric oxide synthase, promote relaxation of the penile chambers to allow for maximum penile engorgement. Eventually, the nitric oxide supply is fully metabolized, revoking its dilatory effects on the penile chambers, and resulting in detumescence.
These vascular occurrences are enabled by numerous other hormonal, neurological and psychological events. There are important neural impulses responsible for redirecting blood flow from the internal pudendal artery into the penile chambers. These can be generated from the brain, or from a reflexive pathway that is a secondary response to pleasurable genital sensations such as touch. Additionally, the correct hormonal milieu must also be present to permit adequate sexual function. The importance of psychological health in successful erectile function is also evidenced by the adverse effects of psychogenic factors such as anxiety, depression and lack of sensate focus.
ED is a condition where a man is unable to acquire or sustain an erection with sufficient rigidity to successfully engage in sexual intercourse. This may occur from a breach in any of the complex systems mentioned. If a man experiences such sexual dysfunction more than 75% of the times he attempts to have intercourse, he is termed 'impotent'.
The safety of sexual activity in patients with heart disease Sexual activity does have well-defined hemodynamic consequences, which can and directly affect the heart. Studies have shown that a person's heart rate, blood pressure and respiratory rate can rise substantially during sex, sometimes paralleling values seen with moderate exertion. All of these factors increase the amount of work the heart is required to do. Some men with underlying heart disease also experience angina (chest pain owing to the heart lacking sufficient oxygen to meet its needs) during sex, which is a symptom that can be a warning sign of an impending heart attack. Standardized measurements of a person's oxygen consumption, which demonstrates the degree of physical exertion the body is experiencing, have shown that at its peak, sexual activity is about as physically strenuous as walking two to four miles per hour. The greatest levels of 'exertion' actually occur during orgasm, which lasts only a brief amount of time. Albeit counterintuitive, these hemodynamic effects are independent of sexual position (ie man-on-top versus man-on-bottom). One study showed that there was no difference in heart rate or blood pressure when comparing these two basic positions, while another showed only a minor decrease in oxygen consumption or exertion with the 'man-onbottom' technique during orgasm. Not surprisingly, a regular exercise training routine can attenuate these hemodynamic responses during sex, and thereby minimize the cardiac risk that sexual exercise might pose.
Several studies have evaluated the risk of having a heart attack after sex. In general, there appears to be a slightly increased risk of having a myocardial infarction (MI) within the first 1-2 h after sex, and no increased risk beyond that time period. The risk of a postcoital MI is the same whether or not there is a history of prior cardiac disease. People with a sedentary lifestyle, however, do seem to be at a mildly increased risk of having a heart attack after sex than their more active counterparts. This is congruent with well-established data that a regular exercise routine can reduce the risk of MI or sudden cardiac death related to physical exertion in general. However, before we start labeling lingerie with cardiac advisories, it should be noted that these risks are small and transient, which make sex, at least from a cardiac standpoint, less threatening than triggers such as anger, emotional stress or other forms of physical exertion that (usually) occur with greater frequency than orgasm.
Perhaps a more common question than the occurrence of a heart attack after sex is when can sex occur after a heart attack? The easiest answer would be that this advice should be individualized between the patient and physician. In 2000, the Princeton Consensus Panel on sexual activity and cardiac risk published some recommendations to assist physicians in advising their patients. 4 These guidelines are based on categorizing patients as low, intermediate or high risk (for having impending subsequent cardiac problems) depending on their extent of heart disease and other medical conditions. Low-risk patients may safely resume their usual sexual activity. Intermediate-risk patients may undergo further cardiac evaluation to help further stratify them as low or high-risk patients, and high-risk patients should be medically stabilized and optimized prior to resuming sexual activity. A simple approach is to consider sex as any other physical activity, which should be resumed with some degree of initial caution and guided by a patient's symptoms. In some cases, exercise testing can help evaluate and reassure patients and physicians of a patient's ability to safely engage in any physically strenuous activity, including sex. 
How to deal with and how to treat ED in cardiac patients
Most recently, selective phosphodiesterase type 5 inhibitors (PDE-5 inhibitors) have taken over the market for treatment of ED. There are three PDE-5 inhibitors that are approved by the FDA in the US: sildenafil (Viagrat Pfizer Inc., approved 3/27/98), vardenafil (Levitrat Bayer Pharmaceuticals, approved 8/19/03), and tadalafil (Cialist Lilly ICOS LLC, approved 11/21/03). Of the three medications, most of the safety and efficacy data come from studies using sildenafil, since it was the first to be approved ( Figure 1 ). All three of these medications act in a similar manner; by altering cellular events, they allow increased and prolonged levels of nitric oxide, which is crucial to enabling relaxation of the penile chambers. Multiple studies have demonstrated that use of these medications improves the number of times a man can successfully complete sexual intercourse (69% in sildenafil-treated patients compared with 22% taking placebo). The success rate is lower in some patient populations, such as those with diabetes (56%) or those who have undergone prostatectomy or radiation therapy (50%). Common side effects include headache, lightheadedness, dizziness, flushing, passing out or distorted vision.
PDE-5 inhibitors and heart disease
When PDE-5 inhibitors were first available, there was unease regarding their safety in patients with heart disease. While initial studies demonstrated that they were generally well tolerated and without a high incidence of severe side effects, these early studies did not include cardiac patients. As these medications act by opening the penile blood chambers, there was concern that they may 'steal' blood from the heart, causing angina or heart damage. Ironically, sildenafil was initially researched as an antianginal cardiac agent, since it also increased blood flow through the coronary arteries. There was also apprehension that cardiac patients may overexert themselves, undergoing physical activity at levels they were not conditioned to performing at. Subsequent studies have been performed in patients with known or highly suspected coronary artery disease, which showed that sildenafil was unlikely to provoke cardiac ischemia (a condition where the heart is not receiving sufficient oxygen) during exercise. The same safety results were seen in patients with well-treated heart failure, as well as in diabetic patients (who are prone to having 'silent' ischemia). There are, however, circumstances where the use of PDE-5 inhibitors is known to be dangerous. The increased level of nitric oxide caused by these medications also relaxes blood vessels outside of the penis, which can lower blood pressure. Patients taking nitrates, which cause blood vessels to relax and thereby lower blood pressure can have a drastic and dangerous blood pressure reduction, if combined with PDE-5 inhibitors (usually, if taken together within 24-48 h for Viagrat and Levitrat, accordingly longer for Cialist). Accordingly, the use of PDE-5 inhibitors is strictly contraindicated in patients who have taken any kind of nitrates (whether it is in oral, sublingual, intravenous or even transdermal form) concurrently. It should be noted that these cumulative hypotensive effects can occur with all NO donators, that is, also with nitroprusside and molsidomin (a nitrate substitute available outside the US). Patients taking antihypertensive medications such alpha-adrenergic receptor blockers should avoid the PDE-5 inhibitors Cialist and Levitrat (but can take Viagrat). However, PDE-5 inhibitors are safe drugs even in combination with most cardiac medications such as drugs for high blood pressure, heart failure or coronary artery disease (except nitrates and other NO donators). Altogether, sexual activity as well as the use of PDE-5 inhibitors can be safely recommended in all patients with stable cardiac conditions.
Conclusion
ED and heart disease are both common diseases that share similar risk factors. Controlling these factors may improve the outcome of both diseases. In most cardiac patients, treatment of ED with PDE-5 inhibitors is safe, as is resumption of sexual activity. Specifically, patients with unstable cardiac conditions, or those using nitrates, may need to undergo further cardiac evaluation, ideally by a cardiologist, before undergoing treatment for ED or engaging in sexual activity. The ideal cooperation for adequate treatment of sexual dysfunction as it has been established in a very few programs in Europe between urologists, cardiologists, psychologists, and sexual therapists is unfortunately far from reality.
